Re: GNRH agonists and adenomyosis

From: Kelly Shanahan (mks@sierra.net)
Mon Mar 31 22:11:33 1997


>31 yo G1P1 came to see me for a third opinion. ... She has intermittant
menorrhagia (10-12 >days despite being on OCPS,) and severe dysmenorrhea, but her dull
>persistant pelvic pain is present constantly. ....
>My scope showed a normal pelvis, no evidence of endometriosis nor adhesions,
>with bilateral flow through the normal appearing fallopian tubes. Her uterus
>is slightly enlarged and globular. >
.... I believe she has adenomyosis, and I know she >wants to wait a year into her marriage before she gets pregnant. There are a
>couple of reports about using GNRH agonists with adenomyosis for pain
>control. .... My thought is to use the GNRH agonist solo
>for three months and if there is relief, then start with add back therapy
>with the highest possible dose that does not cause a return of the pain.
>Whatjathink?
>
>Rick
>

Rick

I think your idea of using the GnRH agonist is very sensible. After all, if Lupron and the like work for endometriosis, which is endometrial glands & stroma outside the uterus, why shouldn't it work for adenomyosis, which is endometrial glands & stroma within the myometrium? Give it a shot. You and she have nothing to lose really.

Kelly

--
Kelly Shanahan, MD
S. lake Tahoe, CA




use when must restrict search to only the ob-gyn-l forum...
Enter search keywords:
Returns per screen: Require all keywords:

Return to  OB-GYN-L Mail a New Message to the Forum: ob-gyn-l@obgyn.net
Forum Administrator: geffrey.klein@obgyn.net
Report Technical Problems: webmaster@obgyn.net
Last Updated: Mon Nov 2 05:21:26 2009

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.